CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Norway's Arctic Bioscience Q3 sales rise 7% as Americas revenue more than doubles

By Reuters News


Overview

  • Norway biotech firm's Q3 sales revenue rose 7% yr/yr, with Americas more than doubling

  • Gross margin improved to 39.7% from 21.6% in Q3 2025

  • Adjusted EBITDA loss narrowed to NOK -5.5 mln from NOK -7.8 mln in Q3 2025


Outlook

  • Company expects continued sales growth in 2026, supported by strong order backlog

  • Company to prioritize supply security and price adjustments to protect margins amid cost inflation

  • Board is evaluating additional financing initiatives to support liquidity


Result Drivers

  • AMERICAS GROWTH - Co said sales in the Americas more than doubled and accounted for nearly half of total sales revenue

  • PRICE INCREASES - Product price adjustments to offset higher raw material costs supported gross profit improvement

  • COST CONTROL - Co said ongoing cost control and lower operating costs contributed to improved results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted EBITDA

-NOK 5.50 mln

Q3 Gross Margin

39.70%

Q3 Gross Profit

NOK 3.70 mln


Reuters Recommended Reads

  • Nov 10 - Norway's Leroy Seafood Q3 operational EBIT jumps on lower farming costs, cuts 2026 forecast

  • Nov 10 - Austevoll Seafood Q3 revenue falls on early closure of Peru's fishing season due to warm seawater

  • Nov 9 - Senseonics Q3 revenue jumps, raises 2026 outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.